Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: Interactions between neurons and astrocytes

Basal Ganglia

Volumn 2, Issue 2, 2012, Pages 57-66

  Estrada Sánchez, Ana María ^a   Rebec, George V ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Ascorbate; Astrocytes; Electrophysiology; Glutamate transport; Huntingtin; Oxidative stress; Transgenic models

Indexed keywords

AMANTADINE; ASCORBIC ACID; CEFTRIAXONE; DIZOCILPINE; EXCITATORY AMINO ACID TRANSPORTER 2; GLUTAMIC ACID; GLUTAMINE; HUNTINGTIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; VESICULAR GLUTAMATE TRANSPORTER 1;

AMINO ACID TRANSPORT; AMINO TERMINAL SEQUENCE; ANIMAL BEHAVIOR; ASTROCYTE; AUTOPSY; BRAIN CORTEX; BRAIN DYSFUNCTION; CELL INTERACTION; CELL LOSS; CLIMBING; COGNITIVE DEFECT; CORPUS STRIATUM; DEATH; DEGENERATIVE DISEASE; DISEASE MODEL; DRUG TARGETING; ELECTROENCEPHALOGRAPHY; EMOTIONAL DISORDER; HERITABILITY; HIPPOCAMPAL CA3 REGION; HIPPOCAMPAL MOSSY FIBER; HUMAN; HUNTINGTON CHOREA; LONG TERM DEPRESSION; MAZE TEST; MOTOR DYSFUNCTION; NERVE CELL; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; NUCLEOTIDE REPEAT; OPEN FIELD BEHAVIOR; PATHOGENESIS; PHENOTYPE; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; REVIEW; SENSORY NERVE; STRIATE CORTEX; THETA RHYTHM; TRANSGENIC ANIMAL;

EID: 84862835713     PISSN: 22105336     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.baga.2012.04.029     Document Type: Review

References (156)

1. Harper P.S. The epidemiology of Huntington's disease. Huntington's disease 2001, 159-197. Oxford University Press, New York. 3rd ed. G. Bates, P.S. Harper, L. Jones (Eds.).
2. Gusella J.F., Wexler N.S., Conneally P.M., Naylor S.L., Anderson M.A., Tanzi R.E., et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 1983, 306:234-238.
3. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983. The Huntington's Disease Collaborative Research Group.
4. Ambrose C.M., Duyao M.P., Barnes G., Bates P.G., Lin S.C., Srinidhi J., et al. Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat. Somat Cell Mol Genet 1994, 20:27-38.
5. Telenius H., Kremer H.P., Theilmann J., Andrew S.E., Almqvist E., Anvret M., et al. Molecular analysis of juvenile Huntington's disease: the major influence on (CAG)n repeat length is the sex of the affected parent. Hum Mol Genet 1993, 2:1535-1540.
6. Nahhas F.A., Garbern J., Krajewski K.M., Roa B.B., Feldman G.L. Juvenile onset Huntington's disease resulting from a very large maternal expansion. Am J Med Genet A 2005, 137:328-331.
7. Zühlke Ch., Reiss O., Bockel B., Lange H., Thies U. Mitotic stability and meiotic variability of the (CAG)n repeat in the Huntington's disease gene. Hum Mol Genet 1993, 2:2063-2067.
8. Rubinsztein D.C., Leggo J., Chiano M., Dodge A., Norbury G., Rosser E., et al. Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington's disease. Proc Natl Acad Sci U S A 1997, 94:3872-3876.
9. MacDonald M.E., Vonsattel J.P., Shrinidhi J., Couropmitree N.N., Cuples L.A., Bird E., et al. Evidence for the GluR6 gene associated with younger onset age of Huntington's disease. Neurology 1999, 53:1330-1332.
10. Wexler N. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntingtońs disease age of onset. Proc Natl Acad Sci U S A 2004, 101:3498-3503. The U.S.-Venezuela collaborative research project.
11. Arning L., Kraus P.H., Valentin S., Saft C., Andrich J., Epplen J.T. NR2A and NR2B receptor gene variations modify age at onset in Huntington's disease. Neurogenetics 2005, 6:25-28.
12. Arning L., Saft C., Wieczorek S., Andrich J., Kraus P.H., Epplen J.T. NR2A and NR2B receptor gene variations modify age at onset in Huntington's disease in a sex-specific manner. Hum Genet 2007, 122:175-182.
13. Lee J.M., Gillis T., Mysore J.S., Ramos E.M., Myers R.H., Hayden M.R. Common SNP-based haplotype analysis of the 4p16.3 Huntington's disease gene region. Am J Hum Genet 2012, 90:434-444.
14. Cattaneo E., Zuccato C., Tartari M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci 2005, 6:919-930.
15. Li S.H., Schilling G., Young W.S., Li X.J., Margolis R.L., Stine O.C., et al. Huntingtońs disease gene (IT15) is widely expressed in human and rat tissue. Neuron 1993, 11:985-993.
16. Trottier Y., Devys D., Imbert G., Saudou F., An I., Lutz Y. Huntingtońs disease protein and discrimination of the normal and mutated form. Nat Genet 1995, 10:104-110.
17. Nicolas G., Devys D., Goldenberg A., Maltete D., Hervé C., Hannequin D. Juvenile Huntington's disease in an 18-month-old boy revealed by global developmental delay and reduced cerebellar volume. Am J Med Genet A 2011, 155:815-818.
18. Rasmussen A., Macias R., Yescas P., Ochoa A., Davila G., Alonso E. Huntington's disease in children: genotype-phenotype correlation. Neuropediatrics 2000, 31:190-194.
19. Goebel H.H., Heipertz R., Scholz W., Iqbal K., Tellez-Nagel I. Juvenile Huntington's chorea: clinical, ultrastructural, and biochemical studies. Neurology 1978, 28:23-31.
20. Huntington G. On Chorea. The Medical and Surgical Reporter 1872; 26:317-21. Re-Edited. J Neuropsychiatry Clin Neurosci 2003, 15:109-112.
21. Lemiere J., Decruyenaere M., Evers-Kiebooms G., Vandenbusschet E., Dom R. Cognitive changes in patients with Huntingtońs disease (HD) and asymptomatic carriers of the HD mutation: a longitudinal follow-up study. J Neurol 2004, 251:935-942.
22. Kremer B. Clinical neurology of Huntington's disease. Huntington's disease 2001, 28-61. Oxford University Press, New York. 3rd ed. G. Bates, P. Harper, L. Jones (Eds.).
23. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985, 44:559-577.
24. Cudkowicz M., Kowall N.W. Degeneration of pyramidal projection neurons in Huntington's disease cortex. Ann Neurol 1990, 27:200-204.
25. Sotrel A., Paskevich P.A., Kiely D.K., Bird E.D., Williams R.S., Myers R.H. Morphometric analysis of the prefrontal cortex in Huntington's disease. Neurology 1991, 41:1117-1123.
26. Macdonald V., Halliday G.M., Trent R.J., McCusker E.A. Significant loss of pyramidal neurons in the angular gyrus of patients with Huntington's disease. Neuropathol Appl Neurobiol 1997, 23:492-495.
27. Gutekunst C.A., Li S.H., Yi H., Mulroy J.S., Kuemmerle S., Jones R., et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci 1999, 19:2522-2534.
28. Menalled L.B. Knock-in mouse models of Huntington's disease. NeuroRx 2005, 2:465-470.
29. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
30. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997, 90:537-548.
31. Schilling G., Becher M.W., Sharp A.H., Jinnah H.A., Duan K., Kotzuk J.A., et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 1999, 8:397-407.
32. Von Hörsten S., Schmitt I., Nguyen H.P., Holzmann C., Schmidt T., Walther T., et al. Transgenic rat model of Huntington's disease. Hum Mol Genet 2003, 12:617-624.
33. Hodgson J.G., Apopyan N., Gutekunts C.A., Leavitt B.R., LePiane F., Singaraja R. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999, 23:181-192.
34. Gray M., Shirasaki D.I., Cepeda C., André V.M., Wilburn B., Lu X.H., et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 2008, 28:6182-6195.
35. Spampanato J., Gu X., Yang X.W., Mody I. Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's disease. Neuroscience 2008, 157:606-620.
36. Bolam J.P., Hanley J.J., Booth P.A., Bevan M.D. Synaptic organization of the basal ganglia. J Anat 2000, 196:527-542.
37. Smith Y., Bevan M.D., Shink E., Bolam J.P. Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience 1998, 86:353-387.
38. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989, 12:366-375.
39. Gerfen C.R., Surmeier D.J. Modulation of striatal projection systems by dopamine. Annu Rev Neurosci 2011, 34:441-466.
40. Reiner A., Albin R.L., Anderson K.D., D'Amato C.J., Penney J.B., Young A.B. Differential loss of striatal projection neurons in Huntington's disease. Proc Natl Acad Sci U S A 1988, 85:5733-5737.
41. Kawaguchi Y., Wilson C.J., Augood S.J., Emson P.C. Striatal interneurons: chemical, physiological and morphological characterization. Trends Neurosci 1995, 18:527-535.
42. Fino E., Venance L. Spike-timing dependent plasticity in striatal interneurons. Neuropharmacology 2011, 60:780-788.
43. Tepper J.M., Koós T., Wilson C.J. GABAergic microcircuits in the neostriatum. Trends Neurosci 2004, 27662-27669.
44. Tepper J.M., Abercrombie E.D., Bolam J.P. Basal ganglia macrocircuits. Prog Brain Res 2007, 160:3-7.
45. Centonze D., Gubellini P., Pisani A., Bernardi G., Calabresi P. Dopamine, acetylcholine and nitric oxide systems interact to induce corticostriatal synaptic plasticity. Rev Neurosci 2003, 14:207-216.
46. Centonze D., Pisani A., Bonsi P., Giacomini P., Bernardi G., Calabresi P. Stimulation of nitric oxide-cGMP pathway excites striatal cholinergic interneurons via protein kinase G activation. J Neurosci 2001, 21:1393-1400.
47. Gittis A.H., Leventhal D.K., Fensterheim B.A., Pettibone J.R., Berke J.D., Kreitzer A.C. Selective inhibition of striatal fast-spiking interneurons causes dyskinesias. J Neurosci 2011, 31:15727-15731.
48. Heinsen H., Strik M., Bauer M., Luther K., Ulmar G., Gangnus D., et al. Cortical and striatal neurone number in Huntington's disease. Acta Neuropathol 1994, 88:320-333.
49. Gomide V., Bibancos T., Chadi G. Dopamine cell morphology and glial cell hypertrophy and process branching in the nigrostriatal system after striatal 6-OHDA analyzed by specific stereological tools. Int J Neurosci 2005, 115:557-582.
50. Schousboe A., Sickmann H.M., Bak L.K., Schousboe I., Jajo F.S., Faek S.A., et al. Neuron-glia interactions in glutamatergic neurotransmission: roles of oxidative and glycolytic adenosine triphosphate as energy source. J Neurosci Res 2011, 89:1926-1934.
51. Fernandez-Fernandez S., Almeida A., Bolaños J.P. Antioxidant and bioenergetic coupling between neurons and astrocytes. Biochem J 2012, 443:3-11.
52. Scott D.F., Heathfield K.W.G., Toone B., Margerison J.H. The EEG in Huntington's chorea: a clinical and neuropathological study. J Neurol Neurosurg Psychiatry 1972, 35:97-102.
53. De Tommaso M., De Carlo F., Difruscolo O., Massafra R., Sciruicchio V., Bellotti R. Detection of subclinical brain electrical activity changes in Huntington's disease using artificial neural networks. Clin Neurophysiol 2003, 114:1237-1245.
54. Bylsma F.W., Peyser C.E., Folstein S.E., Folstein M.F., Ross C., Brandt J. EEG power spectra in Huntington's disease: clinical and neuropsychological correlates. Neuropsychologia 1994, 32:137-150.
55. Painold A., Anderer P., Holl A.K., Letmaier M., Saletu-Zyhlarz G.M., Saletu B., et al. Comparative EEG mapping studies in Huntington's disease patients and controls. J Neural Transm 2010, 117:1307-1318.
56. Streletz L.J., Reyes P.F., Zalewska M., Katz L., Fariello R.G. Computer analysis of EEG activity in dementia of the Alzheimer's type and Huntington's disease. Neurobiol Aging 1990, 11:15-20.
57. Painold A., Anderer P., Holl A.K., Letmaier M., Saletu-Zyhlarz G.M., Saletu B., et al. EEG low-resolution brain electromagnetic tomography (LORETA) in Huntingtońs Disease. J Neurol 2011, 258:840-854.
58. Estrada-Sánchez A.M., Montiel T., Segovia J., Massieu L. Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters. Neurobiol Dis 2009, 34:78-86.
59. Scherzinger E., Lurz R., Turmaine M., Mangiarini L., Hollenbach B., Hasenbank R., et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 1997, 90:549-558.
60. Li H., Li S.H., Cheng A.L., Mangiarini L., Bates G.P., Li X.J. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Hum Mol Genet 1999, 8:1227-1236.
61. Li H., Li S.H., Johnston H., Shelbourne P.F., Li X.J. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat Genet 2000, 25:385-389.
62. Li H., Wyman T., Yu Z.X., Li S.H., Li X.J. Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release. Hum Mol Genet 2003, 12:2021-2030.
63. Cepeda C., Hurst R.S., Calvert C.R., Hernández-Echeagaray E., Nguyen O.K., Jocoy E., et al. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci 2003, 23:961-969.
64. Milnerwood A.J., Raymond L.A. Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load. J Physiol 2007, 585:817-831.
65. Höhn S., Dallérac G., Faure A., Urbach Y.K., Nguyen H.P., Riess O., et al. Behavioral and in vivo electrophysiological evidence for presymptomatic alteration of prefrontostriatal processing in the transgenic rat model for Huntington's disease. J Neurosci 2011, 31:8986-8997.
66. Klapstein G.J., Fisher R.S., Zanjani H., Cepeda C., Jokel E.S., Chesselet M.F., et al. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J Neurophysiol 2001, 86:2667-2677.
67. Traficante A., Riozzi B., Cannella M., Rampello L., Squitieri F., Battaglia G. Reduced activity of cortico-striatal fibers in the R6/2 mouse model of Huntington's disease. Neuroreport 2007, 18:1997-2000.
68. Cummings D.M., André V.M., Uzgil B.O., Gee S.M., Fisher Y.E., Cepeda C. Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease. J Neurosci 2009, 29:10371-10386.
69. Gu X., Li C., Wei W., Lo V., Gong S., Li S.H., et al. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 2005, 5(46):433-444.
70. Gambazzi L., Gokce O., Seredenina T., Katsyuba E., Runne H., Markram H., et al. Diminished activity-dependent brain-derived neurotrophic factor expression underlies cortical neuron microcircuit hypoconnectivity resulting from exposure to mutant huntingtin fragments. J Pharmacol Exp Ther 2010, 335:13-22.
71. Izhikevich E.M., Desai N.S., Walcott E.C., Hoppensteadt F.C. Bursts as a unit of neural information: selective communication via resonance. Trends Neurosci 2003, 26:161-167.
72. Lisman J.E. Bursts as a unit of neural information: making unreliable synapses reliable. Trends Neurosci 1997, 20:38-43.
73. Walker A.G., Miller B.R., Fritsh J.N., Barton S.J., Rebec G.V. Altered information processing in the proforntal cortex of Huntingtońs disease mouse models. J Neurosci 2008, 28:8973-8982.
74. Berke J.D., Okatan M., Skurski J., Eichenbaum H.B. Oscillatory entrainment of striatal neurons in freely moving rats. Neuron 2004, 43:883-896.
75. Burns S.P., Xing D., Shapley R.M. Comparisons of the dynamics of local field potential and multiunit activity signals in macaque visual cortex. J Neurosci 2010, 30:13739-13749.
76. Buzsáki G., Chrobak J.J. Synaptic plasticity and self-organization in the hippocampus. Nat Neurosci 2005, 8:1418-1420.
77. Walker A.G., Ummel J.R., Rebec G.V. Reduced expression of conditioned fear in the R6/2 mouse model of Huntingtońs disease is related to abnormal activity in prelimbic cortex. Neurobiol Dis 2011, 43:379-387.
78. Levine M.S., Klapstein G.J., Koppel A., Gruen E., Cepeda C., Vargas M.E., et al. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knock in mouse models of Huntington's disease. J Neurosci Res 1999, 58:515-532.
79. Cepeda C., Ariano M.A., Calvert C.R., Flores-Hernández J., Chandler S.H., Leavitt B.R., et al. NMDA receptor function in mouse models of Huntington's disease. J Neurosci Res 2001, 66:525-539.
80. Laforet G.A., Sapp E., Chase K., McIntyre C., Boyce F.M., Campbell M., et al. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J Neurosci 2001, 21:9112-9123.
81. Rebec G.V., Conroy S.K., Barton S.J. Hyperactive striatal neurons in symptomatic Huntington R6/2 mice. Variations with behavioral state and repeated ascorbate treatment. Neuroscience 2006, 137:327-336.
82. Miller B.R., Walker A.G., Shah A.S., Barton S.J., Rebec V.G. Dysregulated information processing by medium spiny neurons in striatum of freely behaving mouse models of Huntington's disease. J Neurophysiol 2008, 100:2205-2216.
83. Miller B.R., Walker A.G., Barton S.J., Rebec G.V. Dysregulated neuronal activity patterns implicate corticostriatal circuit dysfunction in multiple rodent models of Huntington's disease. Front Syst Neurosci 2011, 5:1-10.
84. Miller B.R., Walker A.G., Fowler S.C., von Hörsten S., Riess O., Johnson M.A., et al. Dysregulation of coordinated neuronal firing patterns in striatum of freely behaving transgenic rats that model Huntington's disease. Neurobiol Dis 2010, 37:106-113.
85. Miller B.R., Bezprozvanny I. Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium. Future Neurol 2010, 5:735-756.
86. Cayzac S., Delcasso S., Paz V., Jeantet Y., Cho Y.H. Changes in striatal procedural memory coding correlate with learning deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A 2011, 108:9280-9285.
87. Höhn S., Dallérac G., Faure A., Urbach Y.K., Nguyen H.P., Riess O., et al. Behavioral and in vivo electrophysiological evidence for presymptomatic alteration of prefrontostriatal processing in the transgenic rat model for Huntington's disease. J Neurosci 2011, 31:8986-8997.
88. Joshi P.R., Wu N.P., André V.M., Cummings D.M., Cepeda C., Joyce J.A., et al. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington's disease. J Neurosci 2009, 29:2414-2427.
89. André V.M., Cepeda C., Levine M.S. Dopamine and glutamate in Huntington's disease: a balancing act. CNS Neurosci Ther 2010, 16:163-178.
90. André V.M., Cepeda C., Fisher Y.E., Huynh M., Bardakjian N., Singh S., et al. Differential electrophysiological changes in striatal output neurons in Huntington's disease. J Neurosci 2011, 31:1170-1182.
91. André V.M., Fisher Y.E., Levine M.S. Altered balance of activity in the striatal direct and indirect pathways in mouse models of Huntington's disease. Front Syst Neurosci 2011, 5:46.
92. DeCoteau W.E., Thorn C., Gibson D.J., Courtemanche R., Mitra P., Kubota Y., et al. Oscillations of local field potentials in the rat dorsal striatum during spontaneous and instructed behaviors. J Neurophysiol 2007, 97:3800-3805.
93. Groiss S.J., Elben S., Reck C., Voges J., Wojtecki L., Schnitzler A. Local field potential oscillations of the globus pallidus in Huntington's disease. Mov Disord 2011, 26:2577-2578.
94. Rebec G.V., Barton S.J., Marseilles A.M., Collins K. Ascorbate treatment attenuates the Huntington behavioral phenotype in mice. Neuroreport 2003, 14:1263-1265.
95. Hong S.L., Barton S.J., Rebec G.V. Altered neural and behavioral dynamics in Huntington's disease: an entropy conservation approach. PLoS One 2012, 7:e30879.
96. Díaz-Hernández M., Torres-Peraza J., Salvatori-Abarca A., Morán M.A., Gómez-Ramos P., Alberch J., et al. Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease. J Neurosci 2005, 25:9773-9781.
97. Hassel B., Dingledine R. Glutamate. Basic neurochemistry: molecular, cellular and medical aspects 2006, 267-290. Elsevier Academic Press, Canada. 7th ed. G.J. Siegel, R.W. Albers, S.T. Brady, D.L. Price (Eds.).
98. Kim C.H., Lee J., Lee J.-Y., Roche K.W. Metabotropic glutamate receptors: phosphorylation and receptor signaling. J Neurosci Res 2008, 86:1-10.
99. 2+ signalling in cortical astrocytes. Cell Calcium 2010, 48:225-231.
100. Bezzi P., Gundersen V., Galbete J.L., Seifert G., Steinhäuser C., Pilati E., et al. Astrocytes contain a vesicular compartment that is competent for regulated exocytosis of glutamate. Nature Neurosci 2004, 7:613-620.
101. Hamilton N.B., Attwell D. Do astrocytes really exocytose neurotransmitters?. Nat Rev Neurosci 2010, 11:227-238.
102. Danbolt N.C. Glutamate uptake. Prog Neurobiol 2001, 65:1-105.
103. Arriza J.L., Fairman W.A., Wadiche J.I., Murdoch G.H., Kavanaugh M.P., Amara S.G. Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J Neurosci 1994, 14:5559-5569.
104. Chen W., Aoki C., Mahadomrongkul V., Gruber C.E., Wang G.J., Blitzblau R., et al. Expression of a variant form of the glutamate transporter GLT1 in neuronal cultures and in neurons and astrocytes in the rat brain. J Neurosci 2002, 22:2142-2152.
105. Chen W., Mahadomrongkul V., Berger U.V., Bassan M., DeSilva T., Tanaka K., et al. The glutamate transporter GLT1a is expressed in excitatory axon terminals of mature hippocampal neurons. J Neurosci 2004, 24:1136-1148.
106. Rothstein J.D., Dykes-Hober M., Pardo C.A., Bristol L.A., Jin L., Kuncl R.W., et al. Knock out of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996, 16:675-686.
107. Chen Y., Swanson R. The glutamate transporter EAAT2 and EAAT3 mediates cysteine uptake in cortical neurons cultures. J Neurochem 2003, 84:1332-1339.
108. Yernool D., Boudker O., Jin Y., Gouaux E. Structure of a glutamate transporter homologue from Pyrococcus horikoshii. Nature 2004, 431:811-818.
109. Watzke N., Bamberg E., Grewer C. Early intermediates in the transport cycle of the neuronal excitatory amino acid carrier EAAC1. J Gen Physiol 2001, 117:547-562.
110. Boudker O., Ryan R.M., Yernool D., Shimamoto K., Gouaux E. Coupling substrate and ion binding to extracellular gate of a sodium-dependent aspartate transporter. Nature 2007, 445:387-393.
111. Rose E.M., Koo J.C., Antflick J.E., Ahmed S.M., Angers S., Hampson D.R. Glutamate transporter coupling to Na,K-ATPase. J Neurosci 2009, 29:8143-8155.
112. Genda E.N., Jackson J.G., Sheldon A.L., Locke S.F., Greco T.M., O'Donnell J.C., et al. Co-compartmentalization of the astroglial glutamate transporter, GLT-1, with glycolytic enzymes and mitochondria. J Neurosci 2011, 31:18275-18288.
113. Estrada Sánchez A.M., Mejía-Toiber J., Massieu L. Excitotoxic neuronal death and the pathogenesis of Huntington's disease. Arch Med Res 2008, 39:265-276.
114. Cross A.J., Slater P., Reynolds G.P. Reduced high-affinity glutamate uptake sites in the brains of patients with Huntington's disease. Neurosci Lett 1986, 67:198-202.
115. Arzberger T., Krampfl K., Leimgruber S., Weindl A. Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease-an in situ hybridization study. J Neuropathol Exp Neurol 1997, 56:440-454.
116. Faideau M., Kim J., Cormier K., Gilmore R., Welch M., Auregan G., et al. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Hum Mol Genet 2010, 19:3053-3067.
117. Hassel B., Tessler S., Faull R.L., Emson P.C. Glutamate uptake is reduced in prefrontal cortex in Huntington's disease. Neurochem Res 2008, 33:232-237.
118. Liévens J.C., Woodman B., Mahal A., Spasic-Boscovic, Samuel D., Kerkerian-Le Goff, et al. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol Dis 2001, 8:807-821.
119. Behrens P.F., Franz P., Woodman B., Lindenberg K.S., Landwehrmeyer G.B. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington's mutation. Brain 2002, 125:1908-1922.
120. Shin J.Y., Fang Z.H., Yu Z.X., Wang C.E., Li S.H., Li X.J. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol 2005, 171:1001-1012.
121. Miller B.R., Dorner J.L., Shou M., Sari Y., Barton S.J., Sengelaub D.R., et al. Up-regulation of GLT-1 expression increases glutamate uptake and attenuates the Huntingtońs disease phenotype in the R6/2 mouse. Neuroscience 2008, 153:329-337.
122. Nicniocaill B., Haraldsson B., Hansson O., O'Connor W.T., Brundin P. Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice. Eur J Neurosci 2001, 13:206-210.
123. Huang K., Kang M.H., Askew C., Kang R., Sanders S.S., Wan J., et al. Palmitoylation and function of glial glutamate transporter-1 is reduced in the YAC128 mouse model of Huntington's disease. Neurobiol Dis 2010, 40:207-215.
124. Bradford J., Shin J.Y., Roberts M., Wang C.E., Li X.J., Li S. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci U S A 2009, 106:22480-22485.
125. Rothstein J.D., Patel S., Regan M.R., Haenggeli C., Huang Y.H., Bergles D.E., et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005, 433:73-77.
126. Miller B.R., Dorner J.L., Bunner K.D., Gaither T.W., Klein E.L., Barton S.J., et al. Up-regulation of GLT1 reverses the deficit in cortically evoked striatal ascorbate efflux in the R6/2 mouse model of Huntington's disease. J Neurochem 2012, 121:629-638.
127. Omrani A., Melone M., Bellesi M., Safiulina V., Aida T., Tanaka K., et al. Up-regulation of GLT-1 severely impairs LTD at mossy fibre-CA3 synapses. J Physiol 2009, 587:4575-4588.
128. Bellesi M., Melone M., Gubbini A., Battistacci S., Conti F. GLT-1 upregulation impairs prepulse inhibition of the startle reflex in adult rats. Glia 2009, 57:703-713.
129. Bellesi M., Vyazovskiy V.V., Tononi G., Cirelli C., Conti F. Reduction of EEG theta power and changes in motor activity in rats treated with ceftriaxone. PLoS One 2012, 7:e34139.
130. Chinoy N.J. Ascorbic acid levels in mammalian tissues and its metabolic significance. Comp Biochem Physiol A Comp Physiol 1972, 42:945-952.
131. Schreiber M., Trojan S. Ascorbic acid in the brain. Physiol Res 1991, 40:413-418.
132. Rebec G.V., Pierce R.C. A vitamin as neuromodulator: ascorbate release into the extracellular fluid of the brain regulates dopaminergic and glutamatergic transmission. Prog Neurobiol 1994, 43:537-565.
133. Rebec G.V., Barton S.J., Ennis M.D. Dysregulation of ascorbate release in the striatum of behaving mice expressing the Huntington's disease gene. J Neurosci 2002, 22:RC202.
134. Dorner J.L., Miller B.R., Barton S.J., Brock T.J., Rebec G.V. Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease. Behav Brain Res 2007, 178:90-97.
135. Dorner J.L., Miller B.R., Klein E.L., Murphy-Nakhnikian A., Andrews R.L., Barton S.J., et al. Corticostriatal dysfunction underlies diminished striatal ascorbate release in the R6/2 mouse model of Huntington's disease. Brain Res 2009, 1290:111-120.
136. Rebec G.V. From interferant anion to neuromodulator: ascorbate oxidizes its way to respectability. Electrochemical methods for neuroscience 2009, 149-165. CRC Press, Boca Raton, FL. A.C. Michael, L.M. Borland (Eds.).
137. Tkac I., Dubinsky J.M., Keene C.D., Gruetter R., Low W.C. Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo 1H NMR spectroscopy. J Neurochem 2007, 100:1397-1406.
138. Ghasemzadeh B., Cammack J., Adams R.N. Dynamic changes in extracellular fluid ascorbic acid monitored by in vivo electrochemistry. Brain Res 1991, 547:162-166.
139. Grunewald R.A., Fillenz M. Release of ascorbate from synaptosomal fraction of rat brain. Neurochem Int 1984, 6:491-500.
140. Miele M., Boutelle M.G., Fillenz M. The physiologically induced release of ascorbate in rat brain is dependent on impulse traffic, calcium influx and glutamate uptake. Neuroscience 1994, 62:87-91.
141. Trotti D., Rizzini B.L., Rossi D., Haugeto O., Racagni G., Danbolt N.C., et al. Neuronal and glial glutamate transporters possess an SH-based redox regulatory mechanism. Eur J Neurosci 1997, 9:1236-1243.
142. Harrison F.E., May J.M. Vitamin C function in the brain: vital role of the ascorbate transporter SVCT2. Free Radic Biol Med 2009, 46:719-730.
143. Kiyatkin E.A., Rebec G.V. Ascorbate modulates glutamate-induced excitations of striatal neurons. Brain Res 1998, 812:14-22.
144. Liu J., Wu C., Liu W., Zhang H., Li C.L. Involvement of the corticostriatal glutamatergic pathway in ethanol-induced ascorbic acid release in rat striatum. Addict Biol 1999, 4:273-281.
145. Pierce R.C., Rebec G.V. Dopamine-, NMDA- and sigma-receptor antagonists exert differential effects on basal and amphetamine-induced changes in neostriatal ascorbate and DOPAC in awake, behaving rats. Brain Res 1992, 579:59-66.
146. Portugal C.C., Miya V.S., Calaza Kda C., Santos R.A., Paes-de-Carvalho R. Glutamate receptors modulate sodium-dependent and calcium-independent vitamin C bidirectional transport in cultured avian retinal cells. J Neurochem 2009, 108:507-520.
147. Pierce R.C., Miller D.W., Reising D.B., Rebec G.V. Unilateral neostriatal kainate, but not 6-OHDA, lesions block dopamine agonist-induced ascorbate release in the neostriatum of freely moving rats. Brain Res 1992, 597:138-143.
148. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
149. Liévens J.C., Rival T., Iché M., Chneiweiss H., Birman S. Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in Drosophila. Hum Mol Genet 2005, 14:713-724.
150. Trotti D., Rossi D., Gjesdal O., Levy L.M., Racagni G., Danbolt N.C., et al. Peroxynitrite inhibits glutamate transporter subtypes. J Biol Chem 1996, 271:5976-5979.
151. Estrada Sanchez A.M., Massieu L. Role of oxidative stress in the pathogenesis of Huntington's disease. New perspective on brain cell damage, neurodegeneration and neuroprotective strategies 2007, 21-36. Research Signpost, Kerala, India. A. Santamaría, M.E. Jiménez-Capdeville (Eds.).
152. Chen C.M. Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease. Chang Gung Med J 2011, 34:135-152.
153. Browne S.E., Beal M.F. The energetics of Huntington's disease. Neurochem Res 2004, 29:531-546.
154. Estrada-Sánchez A.M., Montiel T., Massieu L. Glycolysis inhibition decreases the levels of glutamate transporters and enhances glutamate neurotoxicity in the R6/2 Huntington's disease mice. Neurochem Res 2010, 35:1156-1163.
155. Liu X., Miller B.R., Rebec G.V., Clemmer D.E. Protein expression in the striatum and cortex regions of the brain for a mouse model of Huntington's disease. J Proteome Res 2007, 6:3134-3142.
156. Li X., Valencia A., Sapp E., Masso N., Alexander J., Reeves P., et al. Aberrant rab11-dependent trafficking of the neuronal glutamate transporter EAAC1 causes oxidative stress and cell death in Huntington's disease. J Neurosci 2010, 30:4552-4561.